Duff & Phelps Investment Management Co. Sells 9,378 Shares of Danaher Co. (NYSE:DHR)

Duff & Phelps Investment Management Co. lowered its stake in shares of Danaher Co. (NYSE:DHR) by 13.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,898 shares of the conglomerate’s stock after selling 9,378 shares during the quarter. Duff & Phelps Investment Management Co.’s holdings in Danaher were worth $14,466,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Tsfg LLC increased its holdings in shares of Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. bought a new position in Danaher during the second quarter valued at about $25,000. nVerses Capital LLC acquired a new position in Danaher in the 2nd quarter valued at approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in Danaher in the 1st quarter valued at approximately $30,000. Finally, Richardson Financial Services Inc. bought a new stake in shares of Danaher in the 4th quarter worth approximately $42,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on DHR shares. The Goldman Sachs Group upped their target price on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Evercore ISI decreased their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Leerink Partners increased their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Finally, Robert W. Baird lifted their price objective on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and an average price target of $278.94.

Insider Activity at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $5,566,486.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now owns 29,407 shares in the company, valued at $8,229,254.88. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Down 0.4 %

Shares of DHR opened at $275.44 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The company has a market cap of $204.01 billion, a price-to-earnings ratio of 46.68, a PEG ratio of 4.55 and a beta of 0.83. The stock has a fifty day moving average price of $270.23 and a two-hundred day moving average price of $257.87. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the business posted $2.05 earnings per share. The firm’s revenue for the quarter was down 2.9% compared to the same quarter last year. Analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.39%. Danaher’s dividend payout ratio (DPR) is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.